Ikena Oncology Inc reports results for the quarter ended March 31 - Earnings Summary

• Ikena Oncology Inc IKNA.OQ reported a quarterly adjusted loss of 18 cents​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of -33 cents. The mean expectation of three analysts for the quarter was for a loss of 21 cents per share. Wall Street expected results to range from -25 cents to -17 cents per share.

• Reported revenue was zero​; analysts expected zero.

• Ikena Oncology Inc's reported EPS for the quarter was a loss of 18 cents​.

• The company reported a quarterly loss of $8.62 million.

• Ikena Oncology Inc shares had fallen by 11.7% this quarter and lost 31.1% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 2.3% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Ikena Oncology Inc is $3.00

This summary was machine generated from LSEG data May 12 at 12:00 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)